| Astellas and Vical Announce Initiation of Phase II Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients|
Astellas Pharma Global Development, Inc. announced the initiation of a Phase II trial of ASP0113 in approximately 140 solid organ transplant recipients. The global, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of ASP0113 compared to placebo as measured by the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. [Astellas Pharma Global Development, Inc.] Press Release
Researchers Evaluating Immunotherapy Approaches for Treating Metastatic Kidney, Prostate, Bladder Cancers
Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. One of the studies will assess how patients’ immune systems respond to targeted radiation treatments for metastatic kidney cancer. Another will evaluate how patients’ immune systems respond to targeted radiation treatments for metastatic prostate cancer, in combination with immunotherapy, and a third will focus on a new type of immunotherapy for bladder cancer. [Roswell Park Cancer Institute] Press Release
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.